Search

EHA Guidelines on Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults.

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

Oct 06 2021

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Research & Mentoring

One of EHA’s key pillars is investing in future leaders in hematology.

Late-Breaking Abstract Submission

Late-breaking abstract procedureThe official late-breaking abstract submission was open from May 3 to 9, 2024 (09:00 CEST). The full late-breaking abstract submission terms & conditions can be found here.